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Current and emerging treatment options 
for ANCA-associated vasculitis: potential role 
of belimumab and other BAFF/APRiL targeting 
agents
Aleksander Lenert1
Petar Lenert2
1Division of Rheumatology, University 
of Kentucky, Kentucky Clinic, 
Lexington, KY, USA; 2Division of 
immunology, Department of internal 
Medicine, The University of iowa, 
iowa City, iA, USA
Abstract: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) 
comprises several clinical entities with diverse clinical presentations, outcomes, and nonunifying 
pathogenesis. AAV has a clear potential for relapses, and shows unpredictable response to 
treatment. Cyclophosphamide-based therapies have remained the hallmark of induction therapy 
protocols for more than four decades. Recently, B-cell depleting therapy with the anti-CD20 
antibody rituximab has proved beneficial in AAV, leading to Food and Drug Administration 
approval of rituximab in combination with corticosteroids for the treatment of AAV in adults. 
Rituximab for ANCA-associated vasculitis and other clinical trials provided clear evidence 
that rituximab was not inferior to cyclophosphamide for remission induction, and rituximab 
appeared even more beneficial in patients with relapsing disease. This raised hopes that other 
B-cell-targeted therapies directed either against CD19, CD20, CD22, or B-cell survival factors, 
B-cell activating factor of the tumor necrosis factor family (BAFF) and a proliferation-inducing 
ligand could also be beneficial for the management of AAV. BAFF neutralization with the fully 
humanized monoclonal antibody belimumab has already shown success in human systemic lupus 
erythematosus and, along with another anti-BAFF reagent blisibimod, is currently undergoing 
Phase II and III clinical trials in AAV. Local production of BAFF in granulomatous lesions and 
elevated levels of serum BAFF in AAV provide a rationale for BAFF-targeted therapies not only 
in AAV but also in other forms of vasculitis such as Behcet’s disease, large-vessel vasculitis, or 
cryoglobulinemic vasculitis secondary to chronic hepatitis C infection. BAFF-targeted therapies 
have a very solid safety profile, and may have an additional benefit of preferentially targeting 
newly arising autoreactive B cells over non-self-reactive B cells.
Keywords: B-cell-activating factor of the TNF family, a proliferation-inducing ligand, 
antineutrophil cytoplasmic antibody-associated vasculitis, granulomatosis with polyangiitis, 
microscopic polyangiitis, B cells
Insight into the classification, pathogenesis, 
and current management of AAV
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) includes 
several life-threatening forms of vasculitis: granulomatosis with polyangiitis (GPA), 
microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis 
(EGPA), and renal-limited vasculitis. The connecting pathologic feature of this group 
of diseases is a necrotizing small-vessel vasculitis commonly affecting multiple organs, 
including lungs and kidneys (pulmonary–renal syndromes).1 Despite grouping them 
together under the umbrella of AAV, there are significant clinical and pathophysiologic 
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differences between these diseases with implications for 
treatment. These diseases typically present with high titer 
ANCA. Two major ANCA targets are proteinase 3 (PR3-
ANCA), giving rise to cytosplasmic (C)-ANCA pattern, 
and myeloperoxidase (MPO-ANCA), which gives rise to 
perinuclear (P)-ANCA pattern on ethanol-fixed neutro-
phils. These antigens are found within the cytoplasm of 
neutrophils, but can also be found on the cell surface of a 
subset of neutrophils.1,2 Occasionally, other autoantigens 
can be targeted by ANCA, such as cathepsin G, lactofer-
rin, lysozyme, bacterial permeability increasing factor, 
hLAMP-2, and elastase. Atypical P-ANCA staining can 
sometimes be found in other diseases, such as inflammatory 
bowel disease, rheumatoid arthritis (RA), cystic fibrosis, and 
primary sclerosing cholangitis. ANCA can even coexist with 
ANA, as reported in cases of drug-induced vasculitis associ-
ated with chronic hydralazine or minocycline use.3 The role 
of B cells in AAV extends way beyond their role in ANCA 
production. B cells are excellent antigen-presenting cells 
for antigens delivered via their B-cell receptor for antigen. 
When costimulated through their innate receptors (eg, Toll-
like receptors 4, 7, and 9), B cells can upregulate costimula-
tory molecules of the B7 family, allowing them to provide 
a second signal necessary for the cognate T-cell activation. 
They can also secrete proinflammatory cytokines, such as 
interleukin (IL)-6 and tumor necrosis factor (TNF), that can 
downregulate the function of regulatory T cells and boost 
the differentiation of effector T cells. Indeed, the complex 
and delicate interplay between T cells – including circulating 
follicular helper T cells and regulatory T cells – and B cells 
has been observed in GPA patients treated with rituximab. 
Treatment with rituximab, but not conventional therapy, 
resulted in restored balance between follicular helper T cells 
and regulatory T cells, similar to the one seen in healthy 
controls.4 Increased frequencies of effector memory T cells, 
and particularly IL-21-producing follicular helper T cells, 
have been observed in patients with GPA and were restricted 
to ANCA-positive patients.5 Once released, IL-21 enhanced 
in vitro production of immunoglobulin G (IgG) and ANCA 
in GPA patients. Finally, B cells may also have an important 
regulatory function, which is diminished in AAV.6
GPA is a complex systemic disease characterized by 
granulomatous inflammation of the upper airways and 
lungs, together with a predominant small-vessel vasculitis. 
GPA is clinically associated with the presence of ANCA-
targeting PR3-ANCA. A recent large-scale genome-wide 
association study has shown strong genetic predisposition 
for making PR3-ANCA versus MPO-ANCA antibodies.7 
In addition to airway disease, pauci-immune necrotizing 
glomerulonephritis can be seen in up to three-fourths of the 
patients, leading to end-stage renal disease in 20%–25% of 
patients within 5 years. Over the same time period, clinical 
relapses are seen in up to 50% of patients.2 Unfortunately, 
there are currently no reliable disease biomarkers that can 
sensitively predict flares of GPA in an individual patient. 
Management of GPA varies greatly from one case to other 
based on the extent of systemic involvement (localized/
limited vs multisystemic disease) and relapsing nature of 
the disease. Further difficulties in the management of GPA 
come from a need for prolonged maintenance therapy and 
drug- and disease-related comorbidities.
In contrast to GPA, MPA is characterized by systemic 
small vasculitis, including a very common pauci-immune 
glomerulonephritis, but without evidence of systemic 
granulomatous disease. Serologically, MPA presents with 
MPO-ANCA. Chronic lung damage in MPA, while common, 
tends to assume a more restrictive fibrosing pattern differ-
ent from that seen in GPA and EGPA. Another distinctive 
feature is that MPA has a significantly lower relapse rate 
compared to GPA.2
While the ultimate goal of the treatment of AAV should 
aim at restoring the abnormal immunologic tolerance to 
ANCA-associated autoantigens, such a goal is currently unre-
alistic. We need to better understand what leads to defective 
immunologic checkpoints at different stages of lymphoid 
development, allowing escape and subsequent survival of 
autoreactive T and B cells.
Since its original description of GPA and up to the early 
1970s, the prognosis of GPA was very poor with a very low 
survival rate in critically ill patients. Combined cyclophosph-
amide and corticosteroid treatment, along with hemodialysis 
and ventilator support, was the first promising therapy for this 
deadly disease, first introduced at the National Institutes of 
Health in the early 1970s.8 Thereafter, cyclophosphamide-
based regimens became the standard of care for remission 
induction in GPA, MPA, and severe cases of EGPA. How-
ever, high cumulative dose of cyclophosphamide has been 
associated with serious side effects including infections, bone 
marrow toxicity, infertility, and cancer (particularly bladder 
cancer; acute myeloid leukemia, and non-melanoma skin 
cancer).9 In line with this, a recent study, surprisingly, showed 
that the early mortality in GPA was more commonly associ-
ated with secondary infections due to immunosuppression 
rather than to active vasculitis.10 Early mortality during the 
first year of treatment thus remains a significant clinical prob-
lem, and novel therapies are therefore desperately needed.
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Treatment of AAV (both GPA and MPA) can be divided 
into two phases: induction of remission and maintenance. In 
the first phase, oral cyclophosphamide (dosed 2 mg/kg/day up 
to 150 mg/day and adjusted for renal insufficiency) and high-
dose corticosteroids (pulse IV methylprednisolone followed 
by prednisone 1 mg/kg/day) are employed to rapidly reduce 
inflammation and prevent permanent organ damage. In the 
remission maintenance phase, use of less toxic immunosup-
pression is aimed at reducing the incidence of relapses. The 
toxicity is especially severe in elderly patients and those who 
present with severe renal involvement. Studies have shown 
that cyclophosphamide toxicity can be reduced by switching 
from oral cyclophosphamide to azathioprine once remission 
is achieved, usually within the 3–6 months period. Use of IV 
cyclophosphamide is associated with lower cumulative dose 
and reduced toxicity. However, while a similar remission 
induction rate was observed, the relapse rate was unfortu-
nately higher in those treated with IV cyclophosphamide.2
Methotrexate has also been used in early induction phase, 
but it is less effective than cyclophosphamide and is reserved 
for those with localized/limited disease or those without 
major organ involvement.
Plasma exchange is frequently used in AAV patients, 
particularly in those presenting with severe renal involvement 
resulting in rapidly deteriorating renal function.11 The 
rationale for plasma exchange is to rapidly remove ANCA 
and other inflammatory mediators, before the effect of 
immunosuppressive/anti-inflammatory agents comes into 
play. PEXIVAS, an international, multicenter clinical trial, 
is currently evaluating the benefits from plasma exchange 
in renal recovery and in patients with pulmonary hemor-
rhage (Clinicaltrials.gov NCT00987389, study is recruiting 
participants, no study results provided).
A major breakthrough in the management of the induc-
tion phase of AAV, as an alternative to cyclophosphamide, 
came from Rituximab in ANCA-associated vasculitis 
(RAVE) and RITUXVAS (an international, randomized, 
open-label trial comparing a rituximab-based regimen with 
a standard cyclophosphamide/azathioprine regimen in the 
treatment of active, “generalized” AAV) studies employing 
a B-cell-depleting agent rituximab.12,13 Rituximab (chimeric 
human/mouse anti-CD20 antibody) in combination with 
corticosteroids was not inferior to cyclophosphamide and 
corticosteroids for remission induction in AAV (GPA and 
MPA). The RAVE study enrolled 197 patients with AAV 
(newly diagnosed or relapsing GPA or MPA) allocated to 
induction therapy with rituximab or to daily oral cyclo-
phosphamide (2 mg/kg/day) in addition to corticosteroids. 
After remission, cyclophosphamide was replaced with 
azathioprine. Rituximab dose was 375 mg/m2 and was admin-
istered once weekly for a period of 4 weeks. The primary 
endpoint was complete disease remission and complete taper-
ing of prednisone at 6 months. Sixty-four percent of patients 
in the rituximab group versus 53% in the cyclophosphamide 
group (P0.0001 for non-inferiority) achieved complete 
remission and were steroid-free at 6 months. Furthermore, 
rituximab appeared more effective in inducing remission in 
a subgroup of patients with relapsing disease (67% vs 42%, 
P=0.01).12 However, it is unclear whether rituximab is as 
effective in cases of severe AAV, because patients with severe 
renal failure (creatinine 4 mg/dL) and severe respiratory 
involvement requiring mechanical ventilation were excluded 
from the trial. Thus, current vasculitis experts prefer the use 
of oral cyclophosphamide for cases with severe multisystem 
disease at presentation. Adverse rates were not different 
between treatment groups. In the RITUXVAS study, the 
non-inferiority of rituximab to cyclophosphamide was studied 
in 44 patients with newly diagnosed GPA or MPA compli-
cated with glomerulonephritis. The primary endpoints were 
sustained remission at 12 months and severe adverse events. 
Both groups showed nonsignificant differences. These two 
studies have led to Food and Drug Administration (FDA) 
approval of rituximab in combination with glucocorticoids 
for adults with GPA and MPA. Rituximab should therefore 
be considered equivalent to cyclophosphamide as a first-line 
therapy in patients with GPA and MPA. In those who fail 
both agents, open-label studies suggested a potential benefit 
from alemtuzumab (anti-CD52), anti-TNF antagonists (with 
the caveat that etanercept failed to provide benefits in a larger 
study),14 mycophenolate mofetil, complement inhibitors, 
15-deoxyspergualin, CTLA4-Ig, or IV immunoglobulins.2,15
The cumulative effect of rituximab in AAV is unknown, 
but few cases of John Cunningham (JC) virus infection 
leading to progressive multifocal leukoencephalopathy have 
been reported.16 Besides rituximab, other fully humanized 
anti-CD20 antibodies have been developed (eg, ofatumumab, 
ocrelizumab, and veltuzumab), but none has been approved 
for the treatment of AAV. Another antibody, epratuzumab, 
targets the human CD22 on B cells and works by inducing 
a negative regulation of B cells stimulated via their B-cell 
receptor for antigen and, while it is currently undergoing a 
trial in systemic lupus erythematosus (SLE), it is unclear at 
this time whether it can be beneficial in AAV.
Regarding maintenance therapy for GPA, studies have 
suggested that azathioprine and methotrexate are equivalent 
in maintaining remission,17 with the caveat that methotrexate 
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cannot be used in patients with significant renal dysfunction. 
Leflunomide (high dose of 30 mg/day) could be considered 
as another alternative agent to methotrexate,18 while, 
surprisingly, mycophenolate mofetil was less effective in 
maintaining remission compared to azathioprine.19 The 
optimal duration of maintenance therapy for GPA is unknown 
and is currently undergoing clinical evaluation.
Management of the localized disease remains a very chal-
lenging task and requires a team-based approach between 
rheumatologists, ENT specialists, and ophthalmologists. 
There is a suggestion that rituximab maybe less effective in 
treating localized granulomatous disease compared to gener-
alized disease, particularly in those with orbital masses and 
pachymeningitis.20 However, anecdotal clinical experience 
with rituximab for localized mass lesions has shown promise. 
Older literature suggests that treatment with trimethoprim–
sulfamethoxazole for 24 months may reduce the incidence of 
relapses in upper respiratory GPA, likely through an effect 
on nasal carriage of Staphylococcus aureus.21 Obstructive 
tracheobronchial disease can lead to permanent scarring, 
and is another example of poor responsiveness to systemic 
treatment. Early tracheobronchial disease sometimes 
responds well to intralesional corticosteroids with or without 
intralesional mitomycin-C and endoluminal dilatation.22,23 
Tracheal and bronchial stenosis can predispose patients to 
recurrent chest infections. Reconstructive surgery for saddle 
nose deformity is currently recommended only for patients 
in clinical remission. Local management with intranasal 
glucocorticoids and regular saline washes can help patients 
with chronic nasal crusting and sinusitis. Surgical interven-
tion should be considered in patients who develop obstruction 
of the middle ear.24 However, these recommendations are 
based on limited evidence usually from small case series or 
individual reports.
Minor relapses can be managed with increasing dose 
of oral glucocorticoids or by optimizing the maintenance 
immunosuppressive therapy. Unfortunately, major relapses 
may require a repeat of the induction therapy. Lung and 
upper respiratory involvement in GPA is associated with 
higher relapse rates, and, interestingly, previous relapses are 
predictive of future flares.2,25 In relapsing patients, scheduled 
maintenance therapy with rituximab (MAINRITSAN study) 
appears to be very effective for remission maintenance and is 
superior to azathioprine (5% vs 29% at month 28).26 In that 
study, low-dose rituximab 500 mg was administered at days 
0 and 14, at 6 months, 12 months, and 18 months for the total 
of five infusions. However, this observation by the French 
Vasculitis groups has yet to be verified in a prospective 
clinical trial (RITAZAREM study). This study will compare 
conventional DMARD treatment with fixed-interval courses 
of rituximab for prevention of disease flares.
Therefore, the success of B-cell-depleting therapy with 
rituximab in both induction phase and maintenance phase of 
AAV has opened the entryway for other B-cell-targeted thera-
pies. The purpose of this review is to explore the rationale for 
targeting BAFF, a B-cell survival factor. Neutralization of 
BAFF with the anti-BAFF antibody belimumab has recently 
been approved by FDA for the treatment of SLE and is cur-
rently undergoing Phase II/III clinical trials in vasculitis.
Rationale for targeting BAFF 
in vasculitis
Role of BAFF in B-cell maturation
BAFF is a member of the TNF family, also known as BLyS. 
Other commonly used names for this molecule are TNFSF13b, 
TALL-1, THANK, and zTNF4. BAFF plays a crucial role in 
B-cell development by promoting B-cell survival and transi-
tion from the immature to mature B-cell stage. It also plays a 
role in Ig-class switching and subsequent antibody production 
in vivo. BAFF can costimulate B-cell proliferation and splenic 
B-cell survival in vitro.27–29
BAFF is a transmembrane protein from which, by action 
of furin protease, a biologically active protein is generated 
(soluble BAFF).30At this time, a role for membrane BAFF is 
unknown. Soluble BAFF binds to three different TNF recep-
tors: B-cell maturation antigen (BCMA), transmembrane 
activator and calcium modulator and cyclophilin ligand 
interactor (TACI), and BAFF-R (BR3). BCMA and TACI, 
but not BAFF-R, are also receptors for another B-cell survival 
ligand – a proliferation-inducing ligand (APRIL) (Figure 1).27 
Binding of BAFF to its high-affinity BAFF-R activates the 
NF-κB pathway (both classical and noncanonical pathways) 
and MAPK pathway, leading to the expression of genes 
essential for B-cell survival.31 Besides B cells, BAFF can 
also augment certain Th1 responses in vivo.32
While BAFF appears to have a primary role in promoting 
survival of immature B cells, APRIL appears to act at later 
stages of B-cell development supporting the maintenance of 
plasma cells. Interestingly, switched human memory B cells 
(CD27 +IgD-) may not depend on either BAFF or APRIL.33
A variety of cell types have been shown to be capable 
of making BAFF. While cells of the monocyte/macrophage 
lineage appear to be a primary source of BAFF production 
in vitro, under certain stimulatory conditions neutrophils can 
also express and release BAFF.34
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BAFF – possible pathogenic role  
in systemic autoimmune diseases:  
animal models
Elevated BAFF levels favor positive selection of autoreactive 
B cells and abnormal autoantibody production in animals.35 
While BAFF overexpression cannot rescue highly autoreac-
tive B cells, which are typically deleted during early stages of 
B-cell development, they can save those self-reactive B cells 
normally deleted at the late T2 stage of peripheral B-cell 
development. This has been nicely demonstrated in a model 
of anti-HEL self-reactive B cells.36 BAFF-transgenic mice 
overexpressing BAFF develop a systemic disease closely 
mimicking human SLE and Sjögren’s syndrome character-
ized by excessive autoantibody production, increased periph-
eral B-cell numbers, and hypergammaglobulinemia.37 These 
animals also develop lymphadenopathy and splenomegaly 
and may suffer from arthritis and immune-complex-mediated 
glomerulonephritis.
Several strains of mice that spontaneously develop a 
lupus-like disease (eg, MRL-Faslpr/lpr; and (NZBxNZW)F1) 
have increased serum levels of BAFF during the onset and 
progression of SLE. Neutralization of BAFF in (NZBxNZW)
F1 strains with soluble TACI-Ig fusion protein appeared to be 
beneficial by inhibiting proteinuria and prolonging survival.38 
Therapeutic targeting of BAFF also yielded promising results 
in BXSB mice where abnormal autoimmunity in male mice 
depends on duplication of the functional toll-like receptor-7.33 
SLE-prone NZM 2328 mice deficient in BAFF were largely 
protected from clinically overt spontaneous lupus disease 
and were more resistant to disease-promoting properties of 
interferon (IFN)-α.39,40
On the contrary, mice deficient in BAFF lack transitional 
T2-B cells as well as mature marginal zone and follicular 
B cells, and have significantly reduced spleen weights. 
BAFF-deficient mice appear to have adequate number of 
T1-B cells and B1 cells, and their T-cell zones appear nor-
mal. BAFF-/- mice have a ten-fold reduction in total serum 
Ig level and mount diminished T-cell independent and T-cell 
dependent antibody responses.29
BAFF in human systemic and organ-
specific autoimmune diseases
Like mice, humans with the BAFF-R gene deletion have 
severe B-cell lymphopenia. B cells are arrested at the 
transitional B-cell stage and this condition presents with 
adult onset antibody-deficiency syndrome.41 Humans 
with this condition have diminished numbers of mature 
B cells, eg, follicular, marginal zone, and memory B cells, 
and their T-independent immune responses are severely 
impaired.41
In relation to the possible role of BAFF in autoimmunity, 
several rheumatic diseases such as SLE, Sjögren’s syndrome, 
systemic sclerosis, and RA have all been shown to have 
elevated serum levels of BAFF.42–46 Particularly high levels 
of serum BAFF were observed in patients with Sjögren’s 
syndrome.43,44 High levels of BAFF have been associated with 
high double-stranded DNA (dsDNA) antibody titers in SLE, 
anti-SS-A in primary Sjögren’s syndrome, and rheumatoid 
factor (RF) levels in RA.
Several studies in humans have shown a clear association 
between elevated serum BAFF levels and SLE.47–49 Zhang 
was the first to observe elevated levels of soluble BAFF in 
SLE (and also in RA).42 Patients with higher BAFF levels 
tended to have higher anti-dsDNA antibody levels. Later 
studies confirmed this observation and found a good rela-
tionship between the elevated BAFF levels and subsequent 
increase in lupus disease activity scores, thus identifying 
BAFF as a valid target for SLE treatment.50
Figure 1 BAFF and APRiL receptors in B cells and plasma cells.
Notes: BAFF is expressed as a membrane-bound trimer, which undergoes 
proteolytic cleavage by furin to form a soluble trimer. BAFF binds more strongly to 
BAFF-R, with intermediate affinity to TACI, and much less to BCMA. In contrast to 
BAFF, APRiL is processed intracellularly and is found in the circulation either as a 
trimer, or a multimer associated with proteoglycans. APRiL binds more strongly to 
BCMA, also binds to TACi, but not to BAFF-R. BAFF-R is primarily expressed on 
B cells, and BCMA on plasmablasts/plasma cells.
Abbreviations: APRiL, a proliferation-inducing ligand; BAFF, B-cell-activating 
factor of the TNF family; BCMA, B-cell maturation antigen; TACi, transmembrane 
activator and calcium modulator and cyclophilin ligand interactor.
?????
?????
????
?????????? ??????????????????????
????
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In addition to systemic autoimmune disease, BAFF is 
also elevated in organ-specific autoimmune diseases such as 
Graves’ disease, anti-GBM disease, autoimmune pancreatitis, 
myasthenia gravis, idiopathic thrombocytopenic purpura, and 
multiple sclerosis.32 Interestingly, independent of the auto-
immune disease, increased soluble BAFF levels were also 
found in B-cell malignancies and certain primary antibody 
deficiencies (BTK, BAFF-R, or TACI deficiency).51
BAFF studies in AAv
ANCA directed against PR3 is the principal autoimmune 
target in patients with GPA (formerly Wegener’s granu-
lomatosis). It is believed that ANCA binding to cytokine-
primed neutrophils (eg, granulocyte-colony stimulating 
factor, IFN-γ or TNF-primed neutrophils) or fMLP-treated 
nonprimed neutrophils may initiate neutrophil adhesion, 
transmigration, and endothelial cell injury, as well as MPO 
and PR3 upregulation, in vitro.52 Binding of ANCA to these 
cells may lead to superoxide generation and release of lytic 
enzymes and proinflammatory cytokines/chemokines, such 
as IL-8. Furthermore, short pretreatment with anti-PR3 IgG 
antibodies results in significant cell-surface expression of 
BAFF followed by its shedding into the culture medium. Such 
culture supernatants could further promote BAFF-dependent 
survival of Burkitt’s lymphoma-derived centroblast cell line 
L3055, thus pointing toward possible pathogenic mechanism 
in AAV.53
Intravenous injection of mouse antibodies specific for 
MPO can induce pauci-immune crescentic glomerulonephri-
tis that mimics human disease.54 Another layer of evidence 
for potential pathogenic role of anti-MPO antibodies comes 
from maternal–fetal transfer studies.55 Unfortunately, an 
animal model for PR3-AAV is still missing and has yet to 
be developed. While the persistence of positive ANCA in 
GPA patients after induction of remission with cyclophos-
phamide correlates with increased risk of relapse, there is 
no clear-cut linear correlation between ANCA positivity 
and disease activity, thus raising a need for more sensitive 
disease biomarkers.56
It has been well established that patients with active AAV 
have increased numbers of activated B cells. Autoreactive 
B cells within granulomas may act as antigen-presenting 
cells and may promote T-cell activation through direct 
interaction and/or secretion of proinflammatory cytokines 
(eg, IL-6, TNF-α). Germinal centers, typical of formation 
of tertiary lymphoid organs, have been detected in granu-
lomatous lesions from patients with GPA.57 More impor-
tantly, autoreactive B cells, when compared to those without 
self-reactivity, appear to have heightened dependency on 
BAFF. Excessive BAFF production can rescue at least some 
autoreactive B cells from peripheral deletion, allowing them 
to enter forbidden niches within lymphoid organs.36 While the 
above data support a possible role for B cells in GPA, they 
do not rule out a role for antigen-specific T cells, particularly 
Th17 cells, in line with recent observation of elevated IL-17 
and IL-23 levels in GPA.58
BAFF in GPA (wegener’s granulomatosis)
Edberg, in 2004, was the first to observe elevated levels 
of BAFF in patients with GPA.59 It was later confirmed by 
Krumbholz, who found evidence of elevated serum levels of 
BAFF in a cohort of 46 GPA patients from the Mayo Clinic.60 
Difference in BAFF levels was even more pronounced when 
patients with active untreated disease were compared with 
those treated with glucocorticoids or controls. Interestingly, 
a small subset of healthy donors had a very high serum 
BAFF level, which was stable over time, probably reflecting 
a genetic polymorphism.61 A small study showed no differ-
ence in BAFF levels between patients with limited GPA 
and those with generalized GPA.62 Based on these studies, 
Krumbholz first suggested that neutralization of BAFF may 
provide potential benefits to a subset of chronically relaps-
ing GPA patients.
Evidence of T-cell activation, as reflected by elevation 
of soluble IL-2R and soluble CD30, was found in patients 
with active GPA. These markers were also associated with 
elevated BAFF levels in a longitudinal study where GPA 
patients were followed for 24 months. However, while 
soluble IL-2R, soluble CD30, and IL-10 levels were higher 
at the time of diagnosis and during a relapse, this was not the 
case with BAFF.63 BAFF levels did not differ significantly 
between patients who had a relapse and those without a 
relapse. It also failed to correlate with ANCA positivity.62
Important evidence for the role of BAFF/APRIL in the 
pathogenesis of GPA came from studying mucosal biopsy 
samples, which showed evidence of activated B cells along-
side the PR3-expressing cells and B-cell survival factors 
BAFF and APRIL.64
BAFF in MPO-associated vasculitis 
and eosinophilic GPA (formerly 
Churg–Strauss syndrome)
Schneeweis compared BAFF levels in patients with GPA, 
MPA, and EGPA.65 Elevated levels were observed only in 
those with GPA. In contrast, VCAM-1, a marker for endothe-
lial cell activation, was elevated in all patients with AAV. 
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Opposing results were found in a study directed by Xin 
in People’s Republic of China, which showed significant 
elevation of BAFF in patients with MPO-AAV. Out of 
121 patients with MPO-ANCA that were studied, 100 of 
them had MPA, 18 were diagnosed with GPA, and three had 
renal-limited vasculitis. When compared to healthy controls, 
BAFF levels were significantly elevated in both active dis-
ease and in remission, although patients with active disease 
still had significantly higher levels than those in remission.66 
Serum BAFF correlated well with the Birmingham Vasculitis 
Activity Score (BVAS) and erythrocyte sedimentation rate 
(ESR), but failed to correlate with the MPO-ANCA titer. 
Another B-cell survival factor APRIL, along with BAFF, was 
studied in 37 Japanese patients with MPO-ANCA-associated 
renal vasculitis. Serum BAFF (but not APRIL) appeared be 
a very useful marker for distinguishing patients with active 
vasculitis from those with inactive vasculitis and from those 
with infectious complications.67
BAFF in large-vessel vasculitis (Takayasu 
arteritis and giant-cell arteritis)
Takayasu arteritis (TAK) affects large elastic arteries with 
predilection for the aorta and its main branches. TAK may 
have a very silent clinical course and is typically diagnosed 
late, often at the time when irreversible damage has already 
occurred. Furthermore, the disease may even progress despite 
treatment with glucocorticoids and normal acute-phase 
reactants. Even in those patients deemed to be in clinical 
remission, new angiographic changes could be detected in 
up to 60% of patients. In a small study performed on nine 
patients with TAK, BAFF levels were higher in TAK patients 
compared to healthy controls. BAFF levels tended to dimin-
ish with treatment.68
Giant-cell arteritis (GCA) is the most common form 
of systemic vasculitis in the western world. While GCA 
is traditionally viewed as a T-cell-mediated disease with 
additional roles for dendritic cells and macrophages, a recent 
study evaluated the relationship between B-cell numbers, 
B-cell phenotype, and serum BAFF levels in patients with 
newly diagnosed GCA.69 Active disease was characterized by 
an inverse relationship between decreased B-cell numbers, 
especially low B effector (but not regulatory B) cells, and 
increased serum levels of BAFF. Following corticosteroid 
treatment, serum BAFF and the number of B effector cells 
normalized. One explanation for these findings is that cir-
culating B cells were redistributed during the active phase, 
but quickly returned to peripheral blood during remission. 
These B effector cells showed enhanced ability to make IL-6. 
Few B cells could be found in temporal artery biopsy 
specimens. It is believed that B-cell-derived IL-6 may 
potentiate T-cell-mediated autoimmune responses (Th17 
responses), linking these two arms of the immune system 
together. Indeed, this study found a positive correlation 
between serum BAFF and IL-6 levels. It would be of interest 
to see whether B cell depletion therapy, BAFF neutralization, 
IL-6 receptor blockade, or IL-17A blockade can ameliorate 
disease in patients with GCA.
BAFF in other forms of vasculitis
BAFF has also been studied in Behcet’s disease, Kawasaki 
disease, and hepatitis C-related mixed cryoglobulinemia.
Vasculitis in Behcet’s disease may affect arterial and 
venous blood vessels of any size. Serum BAFF levels were 
found to be elevated in patients with active Behcet’s disease 
compared to healthy subjects.70–72 There was also a positive 
correlation between serum BAFF levels, skin BAFF mRNA 
expression, and extent of skin involvement. Patients with 
vasculitic features tended to have higher BAFF-R expression 
on their B cells. In vitro treatment of B lymphocytes from 
active Behcet’s disease with BAFF resulted in enhanced IgG 
and IL-6 secretion. Increased BAFF levels were further found 
in cerebrospinal fluid (CSF) in patients with neuro-Behcet’s 
disease. BAFF levels correlated with progressive dementia 
and psychosis, but not with myelopathy, aseptic meningitis, 
or serum BAFF levels.73 Another study found a correlation 
between BAFF levels and uveitis.72
A case report found elevated BAFF in a 2-year-old girl 
with Kawasaki’s disease refractory to IVIG treatment.74 
Another report recently confirmed this observation.75
Finally, host genetic background related to BAFF pro-
moter polymorphism and elevated serum BAFF levels were 
found in a subset of patient with hepatitis C virus infection 
complicated with mixed cryoglobulinemia.76,77 This is of 
particular interest, as B-cell-depleting therapy with rituximab 
has shown benefits in this condition.
is BAFF a potential biomarker  
for systemic autoimmune disease  
and vasculitis?
In SLE, relatively good correlation exists between serum 
BAFF, autoantibody levels, and disease activity.42,45
With regard to AAV, reports suggest a possible dif-
ference between patients with GPA and MPO-associated 
vasculitis when it comes to correlation between BAFF and 
disease activity. For example, BAFF, although elevated, did 
not correlate with C-reactive protein (CRP) levels, BVAS, 
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disease extent index, or vasculitis damage index scores in 
GPA patients.62 Moreover, individual serum BAFF levels 
appeared stable over time in up to two-thirds of patients. 
Similar lack of correlation with disease activity was found 
in other studies performed in GPA patients.63 Fluctuations 
in BAFF levels did occur in a minority of patients, but were 
not associated with changes in BVAS scores or other dis-
ease activity measures.62 In contrast, in renal MPO-ANCA 
positive vasculitis patients, there was a significant correla-
tion between BVAS and serum BAFF (r=0.737). However, 
the sensitivity of serum BAFF levels was inferior to serum 
CRP levels, questioning its potential usefulness as a disease 
biomarker.
While BAFF levels were elevated in a subgroup of 
untreated GPA patients, Krumbholz could not find any corre-
lation between serum BAFF and C-ANCA titers, or BAFF and 
disease activity.60 Similar lack of correlation between BAFF 
and ANCA was found in a subsequent longitudinal study57 
and in more recent studies from Norway and Germany.62,65 
There was actually an inverse correlation between ANCA 
and BAFF in a study by Bader et al.62 Again, in contrast to 
GPA, a study in renal vasculitis patients found a significant 
correlation between serum BAFF and ANCA titers.67
Changes in BAFF in patients treated  
with rituximab and in those with 
decreased B-cell numbers
In humans, serum levels of BAFF are highly dependent on 
a number of circulating B cells and expression of BAFF 
receptors. Patients with severe primary antibody deficiencies 
have higher levels of BAFF compared to controls. In line 
with this, mice expressing human BAFF had high levels of 
BAFF in the absence of B cells.51 Similar observations were 
made in several clinical trials that utilized anti-CD20 antibody 
treatment (rituximab) to deplete B cells.53,78,79 For example, 
Holden found increased levels of serum BAFF in PR3-
ANCA-positive vasculitis patients.53 He compared BAFF 
levels before and 1–3 months after rituximab treatment at the 
time when the patients were in clinical remission (BVAS 2) 
and had no detectable peripheral blood B cells. Interestingly, 
the already high BAFF levels were further increased after 
rituximab treatment. One can wonder whether increased 
levels of BAFF may favor selection of autoreactive B cells,35 
potentially increasing the likelihood of GPA relapse. It would 
be of great interest to see whether anti-CD20-mediated B-cell 
depletion followed by treatment with BAFF antagonists may 
provide a longer lasting remission in AAV and decrease the 
number of relapses compared to current standard of care.
Clinical trials with belimumab and other 
anti-BAFF agents in SLe and other 
rheumatic diseases
Belimumab (Lympho-Stat-B, Benlysta®; GlaxoSmithKline 
Plc, London, UK), a monoclonal antibody against BAFF, 
has recently been approved for the treatment of human SLE. 
Furthermore, several other BAFF/APRIL blocking agents are 
currently undergoing clinical trials in SLE, RA, and other 
autoimmune diseases.
Belimumab was the first clinically tested BAFF-neutralizing 
humanized monoclonal antibody directed against soluble 
BAFF. Noticeably, it does not bind to the membrane form. 
It was obtained by initial screening of a human phage dis-
play library against human BAFF. It acts by preventing the 
binding of BAFF to its high-affinity receptors on B cells.80 
Consequently, this leads to apoptotic B-cell death and reduc-
tion in circulating B-cell numbers. Administration of Lympho-
Stat-B to cynomolgus monkeys resulted in decreased numbers 
of B cells in both spleens and mesenteric lymph nodes. BAFF-
blocking antibody primarily depletes naïve IgM+IgD+CD27– B 
cells in humans and their counterparts in mice.31,81
In March 2011, belimumab was approved for the treat-
ment of SLE, thus becoming the first FDA-approved medi-
cation for SLE in the past 50 years. Clinical trials of SLE 
patients with belimumab (plus standard of care) showed 
improved clinical disease activity scores and reduced periph-
eral B-cell numbers. Serologically positive patients with 
SLE responded to this treatment better than serologically 
negative patients. As traditional lupus activity indices such 
as Selena-SLEDAI (Safety of Estrogens in Lupus Erythema-
tosus National Assessment – Systemic Lupus Erythematosus 
Disease Activity Index) and BILAG (British Isles Lupus 
Assessment Group) were not sensitive enough to capture 
partial changes in disease activity, a novel SLE Responder 
Index (SRI) was developed to better access the efficacy of 
belimumab in SLE patients.82 BLISS-52 (BLISS – A Study 
of Belimumab in Subjects With Systemic Lupus Erythema-
tosus) and BLISS-76 were two randomized, multicentric, 
placebo-controlled Phase III clinical trials that assessed the 
safety and efficacy of belimumab (plus standard of care) in 
patients with active (seropositive) SLE.83,84 Patients were 
treated with 1 or 10 mg/kg of belimumab or placebo on 
days 0, 14, 28, and every 28 days thereafter. The primary 
endpoint was the change in SRI from baseline to 52 weeks. 
Both treatment groups reached the primary endpoint. Group 
receiving 10 mg/kg of belimumab started showing signifi-
cant difference at week 16. BLISS-76 was conducted with 
patients enrolled in Europe and North America, who were 
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followed for a total of 76 weeks. Only the 10 mg/kg group 
reached a statistically significant response at week 52 (43.2% 
vs 33.5%). Both treatment groups showed reduced relapse 
rate, increased time to first flare, no worsening in PGA scores, 
reduced prednisone dose, and decreased serologic outcomes. 
Importantly, no safety concerns were noticed between the 
groups. Long-term safety/efficacy study performed over 
the period of 7 years showed sustained improvement in 
lupus disease activity, decreased flares, and reduction in 
autoantibodies.81,85,86
It is estimated that approximately 5% of all SLE patients 
in the US have been treated with belimumab, at least once 
(~15,000 patients).87 Post-marketing experience with beli-
mumab showed that arthritis, rash, and serositis were the most 
common clinical manifestations requiring treatment with 
belimumab with a favorable clinical outcome at 12 months 
and with the ability to taper of corticosteroids. Small number 
of patients received belimumab for stable lupus nephritis and 
CNS lupus with some encouraging results. Results from an 
ongoing clinical trial evaluating belimumab in severe lupus 
nephritis have not yet been released.
In addition to belimumab, other BAFF (and APRIL) 
neutralizing therapeutic agents have recently been devel-
oped (Tables 1–4): tabalumab (LY2127399), blisibimod 
(AMG623), and atacicept (TACI-Ig).
Tabalumab is a fully humanized monoclonal antibody of 
the IgG4 subclass that is capable of neutralizing both soluble 
and membrane-bound forms of BAFF, but not APRIL.88 It 
is unclear at this time which biological role a membrane 
BAFF may have. For example, mice expressing membrane 
BAFF, but lacking soluble BAFF, have similar phenotype to 
BAFF-deficient mice showing marked reduction in B cells 
and serum Ig levels.30 It remains to be determined whether 
combined neutralization of soluble and membrane bound 
BAFF has any advantages over solely blocking soluble 
BAFF. Tabalumab is currently undergoing clinical trials in 
SLE, RA, relapsing or refractory multiple myeloma, mul-
tiple sclerosis, and end-stage renal disease. A Phase III trial 
in RA has recently been suspended by the manufacturer, 
even though a previous trial, at week 16, showed efficacy of 
tabalumab in RA patients with inadequate response to metho-
trexate.88 This study showed a transient reduction in naïve 
B cells and simultaneous increase in CD27+ memory B cells 
along with decreased serum Immunoglobulin M levels. Its 
safety profile was acceptable. A Phase III study in SLE and 
a Phase II study in relapsing remitting multiple sclerosis 
were recently completed, but no clinical results have been 
posted yet.
Blisibimod is a peptibody produced in bacteria (E. coli) 
which, similar to tabalumab, targets both soluble and mem-
brane BAFF. It is undergoing clinical trials in SLE, Immu-
noglobulin A nephropathy, and immune thrombocytopenic 
purpura. Two Phase II trials have been completed, but no 
published data are available. An important caveat, in case of 
Blisibimod, is that the BAFF-binding domain of peptibody 
is completely synthetic and likely immunogenic to the host. 
Neutralizing antibody response may potentially develop and 
decrease the potency of Blisibimod.
Atacicept is a chimeric fusion protein made of the extra-
cellular domain of the TACI receptor attached to the human 
Table 1 Properties of BAFF/APRiL neutralizing reagents
Name Tabalumab Blisibimod Belimumab Atacicept
Manufacturer eli Lilly and Co Anthera Pharmaceuticals GSK/HGS eMD-Serono
Characteristic Human igG4 Peptibody Human igG1, λ TACi-R-igG1-Fc
Neutralization of BAFF/APRIL
Soluble BAFF Yes Yes Yes Yes
Membrane BAFF Yes Yes No Yes
APRiL No No No Yes
Clinical studies SLe SLe SLe (FDA approved) SLe
RA (Phase iii suspended) igA nephropathy RA RA
Multiple myeloma iTP Renal transplantation Multiple sclerosis
Multiple sclerosis vasculitis (GPA, MPA) Sjögren’s syndrome Optic neuritis
end-stage renal disease waldenstrom’s macroglobulinemia
Membranous nephropathy (idiopathic)
Systemic sclerosis
iTP
Myasthenia gravis
vasculitis
Abbreviations: APRiL, a proliferation-inducing ligand; BAFF, B-cell-activating factor of the TNF family; FDA, Food and Drug Administration; GPA, granulomatosis with 
polyangiitis; igA, immunoglobulin A; igG, immunoglobulin G; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; SLe, systemic lupus erythematosus; TACi, transmembrane 
activator and calcium modulator and cyclophilin ligand interactor; GSK, GlaxoSmithKline; HGS, Human Genome Sciences; iTP, idiopathic thrombocytopenic purpura.
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Table 2 Clinical trials with atacicept and belimumab
Comment Clinical trial Phase Status Results Completion Primary outcome
Atacicept (TACI-IgG1 fusion protein)
SLE NCT01972568 ii Recruiting No study results 
posted
Percentage of subjects with SRi response 
at week 24 compared to screening
NCT02070978 ii Not yet 
recruiting
No study results 
posted
Number of subjects with at least one 
SAe – safety study 96 weeks
NCT01369628 ib Terminated No study results 
posted
Nov-11 The nature and incidence of Ae at 12 weeks 
– safety study in patients with LN taking 
mycophenolate mofetil
NCT00624338 ii, iii Completed No study results 
posted
Apr-12 Proportion of patients experiencing a new flare 
as defined by a BILAG score of A or B during 
the 52-week treatment period
NCT00573157 ii, iii Terminated Ginzler eM, 2012 Apr-09 Proportion of subjects with improvement in 
renal response to treatment – LN, combination 
with mycophenolate, terminated safety reason
RA Primary endpoint 
not met
NCT00595413 ii Completed van vollenhoven RF, 
2011
Aug-09 The proportion of subjects achieving an ACR20 
response at week 26 (anti-TNF-naïve RA patients)
Primary endpoint 
not met
NCT00430495 ii Completed Genovese MC, 
2012
Sep-09 Functional status or ACR20 at week 26 in RA 
pts who failed anti-TNF treatment
Hypersensitivity  
events
NCT00664521 ii Completed van vollenhoven RF, 
2012 (abstract)
Oct-10 Nature, incidence, and severity of adverse events 
(safety study) – combination with rituximab
Abbreviations: Ae, adverse event; BiLAG, British isles Lupus Assessment Group; igG, immunoglobulin G; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; SAe, 
serious adverse event; SLe, systemic lupus erythematosus; SRi, SLe responder index; TACi, transmembrane activator and calcium modulator and cyclophilin ligand interactor; 
TNF, tumor necrosis factor; LN, Lupus Nephritis; ACR, American College of Rheumatology.
IgG1 Fc domain. It is different from the above-mentioned 
BAFF-specific reagents by its ability to neutralize not only 
BAFF but also APRIL and heterotrimers made of BAFF/
APRIL combinations. Furthermore, it is the only agent that 
can significantly deplete plasma cells.32 SLE-prone mice 
responded favorably to TACI-Ig, as well as humans with 
SLE in phase Ib studies. However, because of increased rate 
of infection and significant decrease in serum IgG, a recent 
Phase II/III trial in active lupus nephritis was halted. Notice-
ably, in this trial, patients were first started on corticosteroids 
and mycophenolate mofetil, and reduction of serum IgG 
was observed even before atacicept was added.89 Another 
Phase II/III study, which evaluated the effect of atacicept in 
SLE patients without active CNS or renal disease, has been 
completed, but data have not been released yet. Atacicept 
was also studied in relapsing multiple sclerosis (terminated), 
optic neuritis (terminated), and in RA patients who had either 
inadequate response to methotrexate or in those who failed 
anti-TNF treatment. Disease activity actually worsened in 
multiple sclerosis patients, reminding us of the possible role 
of regulatory B cells in animal models of multiple sclerosis 
and lupus.90,91 Both Phase II RA studies failed to meet the 
primary endpoint despite significant reduction in rheuma-
toid factor levels (but not anti-CCP levels),92,93 while a trial 
of atacicept in combination with rituximab in RA patients 
resulted in significantly more allergic events. Thus, it appears 
that atacicept has the greatest potential of causing unac-
ceptable toxicities. A monoclonal antibody solely targeting 
APRIL potentially may be more beneficial for lupus, at least 
based on its effect in animal models of lupus.94
As a next step in targeting BAFF, one can also envision 
development of small-molecule inhibitors of BAFF. For 
example, an exon-skipping approach was used to generate 
∆BAFF, a minor alternative splicing variant of BAFF that 
works as a physiologic inhibitor of BAFF. This was beneficial 
in a mouse model of Sjögren’s syndrome, which is character-
ized by overexpression of BAFF and clinical sialoadenitis.95
why to target BLys/BAFF over B-cell 
depletion in AAv
The question remains: what is the potential advantage of 
indirect targeting of B cells via withdrawal of an important 
survival factor (BAFF) over direct depletion of B cells?
One important reason (already elaborated above) is that 
(some) autoreactive B cells may have a greater dependency 
on BLyS/BAFF for their survival over B cells with non-
autoreactive properties. A favorable safety signal observed 
over a period of 7 years in patients with SLE and diminished 
autoantibody levels are in line with this observation. In 
contrast, nonselective B-cell depletion (with rituximab) has 
been associated with rare but devastating cases of progressive 
multifocal encephalopathy.96
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Furthermore, BAFF may also have a direct effect on 
T cells, and may be involved in generation of Th17 or 
Th1 T cells that are believed to have an important role in 
pathogenesis.
Finally, selective preservation of B cells with regulatory 
properties may have a potential role in fine-tuning B-cell 
responses in autoimmune systemic diseases. However, these 
postulates have yet to be verified clinically.
There are presently two ongoing clinical trials designed 
to address the role of BAFF in AAV. BIANCA-SC (A Study 
of the Efficacy, Safety, and Tolerability of Blisibimod in 
Addition to Methotrexate During Induction of Remission in 
Subjects With ANCA-Associated Small Vessel Vasculitis) 
is a Phase II trial to determine the efficacy and safety of 
blisibimod in addition to methotrexate for induction of remis-
sion in patients with AAV. It is designed to exclude patients 
with severe disease requiring cyclophosphamide treatment. 
This study is not yet recruiting participants. Belimumab in 
Remission of Vasculitis is a Phase III study focused on the 
efficacy and safety of belimumab (10 mg/kg) in combina-
tion with azathioprine for maintenance of remission in GPA 
and MPA. The primary outcome is time to first relapse. This 
study is currently open for enrollment.
Conclusion
Based on overwhelming evidence of increased serum and 
tissue levels of BAFF in AAV and favorable therapeutic 
and safety profile of belimumab in patients with SLE, BAFF 
and possibly APRIL appear to be promising targets for treat-
ment of AAV. While AAV is obviously the first choice for 
treatment with BAFF antagonists, other vasculitides includ-
ing TAK, GCA, and Behcet’s disease may be considered too. 
Table 4 Clinical trials with tabalumab and blisibimod
Clinical trial Phase Status Results Completion Primary outcome
Tabalumab (anti-BAFF)
SLE NCT02041091 iii Recruiting No study results posted Pharmacokinetics
NCT01196091 iii Active, not 
recruiting
No study results posted Proportion of patients achieving an SLe Responder 
index response at week 52
NCT01205438 iii Completed No study results posted Aug-14 Proportion of patients achieving an SLe Responder 
index response at week 52 
NCT01488708 iii By invitation only No study results posted Number of adverse events (baseline to 4 years)
RA NCT01676701 iii Completed No study results posted Aug-13 Pharmacokinetics
NCT00689728 ii Completed Genovese MC, 2013 May-10 Efficacy using ACR50 
NCT00785928 ii Completed Genovese MC, 2013 Jan-10 Efficacy using the ACR50 response rate at week 24
NCT01253226 i Completed No study results posted Aug-11 Safety
NCT01576549 ii Completed No study results posted May-13 Percent change in synovitis scores from baseline 
up to week 16 
NCT00308282 ii Completed Genovese MC, 2013 Jun-07 effectiveness of LY2127399 in treating Rheumatoid 
Arthritis using the ACR20 scale at week 24
NCT01198002 iii Completed No study results posted Dec-12 ACR20 response at week 24
NCT01202760 iii Completed No study results posted Dec-12 ACR20 response at week 24
NCT01202773 iii Completed No study results posted Mar-13 ACR20 response at week 24
NCT00837811 ii Completed No study results posted Jan-11 Safety – Treatment–emergent adverse events and 
serious adverse events
NCT01215942 iii Completed No study results posted Feb-14 Percentage of patients developing anti-LY2127399 
antibodies 
NCT01253291 i Completed No study results posted Sep-13 Safety and tolerability at week 72
Blisibimod (peptibody-anti-BAFF)
SLE NCT01395745 iii Recruiting No study results posted Proportion of patients achieving an SLe Responder 
index response at week 52
NCT02074020 iii Not yet recruiting No study results posted Proportion of responders to the SRi-8 composite 
responder index at week 52
NCT01305746 ii Completed No study results posted Jul-13 Long-term safety in patients with SLe
NCT01162681 ii Completed No study results posted Apr-12 SLE response (up to week 52)-safety/efficacy
AAV (GPA, MPA – induction of remission)
NCT01598857 ii Not yet recruiting No study results posted induction of clinical remission (24 weeks)
excludes those with severe disease that would 
require cytoxan
Abbreviations: AAv, Antineutrophil cytoplasmic antibody-associated vasculitis; BAFF, B-cell-activating factor of the TNF family; GPA, granulomatosis with polyangiitis; MPA, 
microscopic polyangiitis; RA, rheumatoid arthritis; SLe, systemic lupus erythematosus; SRi, SLe Responder index; ACR, American College of Rheumatology.
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Targeting BAFF for the treatment of AAv
In contrast, BAFF as a potential biomarker in AAV appears to 
be less reliable compared to more traditional disease activity 
markers (eg, ESR and CRP). BAFF levels also failed to cor-
relate with ANCA titers. We believe that induction therapy 
with a B-cell-depleting agent (eg, rituximab) followed by 
maintenance therapy with anti-BAFF reagents may result in 
diminished numbers of relapses and provide a safer control 
of AAV compared to currently available treatment protocols. 
Further clinical trials are needed to assess clinical efficacy 
of anti-BAFF agents in AAV.
Disclosure
The authors declare no conflicts of interest in this work.
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